Oncotarget

Research Papers:

Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC)

Ivan Casaburi, Paola Avena, Arianna De Luca, Adele Chimento, Rosa Sirianni, Rocco Malivindi, Vittoria Rago, Marco Fiorillo, Francesco Domanico, Carmela Campana, Anna Rita Cappello, Federica Sotgia, Michael P. Lisanti, Vincenzo Pezzi _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2015; 6:25135-25148. https://doi.org/10.18632/oncotarget.4722

Metrics: PDF 799 views  |   HTML 747 views  |   ?  


Abstract

Ivan Casaburi1,*, Paola Avena1,*, Arianna De Luca1,*, Adele Chimento1, Rosa Sirianni1, Rocco Malivindi1, Vittoria Rago1, Marco Fiorillo1, Francesco Domanico1, Carmela Campana1, Anna Rita Cappello1, Federica Sotgia2, Michael P. Lisanti2, Vincenzo Pezzi1

1Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Italy

2The Breakthrough Breast Cancer Research Unit and the Manchester Centre for Cellular Metabolism, Institute of Cancer Sciences, University of Manchester, UK

*These authors have contributed equally to this work

Correspondence to:

Vincenzo Pezzi, e-mail: v.pezzi@unical.it

Keywords: ERRα, adrenocortical cancer, mitochondria, ATP depletion

Received: May 21, 2015     Accepted: July 17, 2015     Published: July 29, 2015

ABSTRACT

The pathogenesis of the adrenocortical cancer (ACC) involves integration of molecular signals and the interplay of different downstream pathways (i.e. IGFII/IGF1R, β-catenin, Wnt, ESR1). This tumor is characterized by limited therapeutic options and unsuccessful treatments. A useful strategy to develop an effective therapy for ACC is to identify a common downstream target of these multiple pathways. A good candidate could be the transcription factor estrogen-related receptor alpha (ERRα) because of its ability to regulate energy metabolism, mitochondrial biogenesis and signalings related to cancer progression.

In this study we tested the effect of ERRα inverse agonist, XCT790, on the proliferation of H295R adrenocortical cancer cell line. Results from in vitro and in vivo experiments showed that XCT790 reduced H295R cell growth. The inhibitory effect was associated with impaired cell cycle progression which was not followed by any apoptotic event. Instead, incomplete autophagy and cell death by a necrotic processes, as a consequence of the cell energy failure, induced by pharmacological reduction of ERRα was evidenced.

Our results indicate that therapeutic strategies targeting key factors such as ERRα that control the activity and signaling of bioenergetics processes in high-energy demanding tumors could represent an innovative/alternative therapy for the treatment of ACC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4722